Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats

Neurol Res. 2005 Jul;27(5):483-92. doi: 10.1179/016164105X17134.

Abstract

Objectives: This study evaluated the antiapoptotic effect of antiplatelet drugs, aspirin and clopidogrel, and the antioxidant drug, MCI-186, against focal cerebral ischemic rat brain damage.

Methods: Cerebral ischemia was mechanically induced by 2-hour occlusion of the left middle cerebral artery (MCA) using an intraluminal filament followed by 24-hour reperfusion.

Results: The cerebral infarct size was little affected by oral administration of 300 mg/kg aspirin, 30 mg/kg clopidogrel or 100 mg/kg MCI-186, but was significantly reduced by 30 mg/kg cilostazol. However, intravenous administration of 10 mg/kg MCI-186 suppressed the infarct size. DNA fragmentation observed in the cortical tissues corresponding to the penumbral zone was not suppressed by aspirin, clopidogrel or MCI-186, but was significantly suppressed by cilostazol. Increased phosphorylation of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) and Bax protein, and decreased Akt/cyclic AMP response element binding protein (CREB) phosphorylation, including Bcl-2 protein in the vehicle-treated group were not affected by treatment with aspirin, clopidogrel and MCI-186, whereas those effects were reversed by cilostazol.

Conclusion: Thus, it is suggested that antiplatelet drugs, aspirin and clopidogrel, and antioxidant drug, MCI-186, showed little antiapoptotic effect in contrast to cilostazol.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antioxidants / therapeutic use*
  • Antipyrine / analogs & derivatives*
  • Antipyrine / therapeutic use
  • Aspirin / therapeutic use*
  • Blotting, Western / methods
  • Brain Edema / drug therapy
  • Brain Edema / metabolism
  • Brain Ischemia / complications
  • Cerebral Infarction / prevention & control
  • Clopidogrel
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • DNA Fragmentation / drug effects
  • Disability Evaluation
  • Dose-Response Relationship, Drug
  • Drug Administration Routes
  • Edaravone
  • Functional Laterality
  • Gene Expression Regulation / drug effects
  • Hypoxia, Brain / etiology
  • Hypoxia, Brain / prevention & control*
  • Male
  • PTEN Phosphohydrolase
  • Phosphoric Monoester Hydrolases / metabolism
  • Phosphorylation / drug effects
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-akt
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use
  • Tumor Suppressor Proteins / metabolism
  • bcl-2-Associated X Protein

Substances

  • Antioxidants
  • Bax protein, rat
  • Cyclic AMP Response Element-Binding Protein
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Tumor Suppressor Proteins
  • bcl-2-Associated X Protein
  • Clopidogrel
  • Akt1 protein, rat
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Phosphoric Monoester Hydrolases
  • PTEN Phosphohydrolase
  • Ticlopidine
  • Aspirin
  • Edaravone
  • Antipyrine